More recently, these results have been confirmed by the REGENERATE-DCM clinical trial [30], in which a 5.37% increase in left ventricular ejection fraction (LVEF) was observed at 3 months after treatment with autologous BM-derived cells combined with peripheral granulocyte colony-stimulating factor (G-CSF). The gene discussed is CSF3; the disease is familial dilated cardiomyopathy.